Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 55, Issue 10, Pages 1159-1184Publisher
SPRINGER
DOI: 10.1007/s00262-006-0164-4
Keywords
epigenetics; chromatin; immune escape; tumor immunity; tumor vaccine; clinical trials
Categories
Funding
- NCI NIH HHS [R01 CA124971] Funding Source: Medline
- NICHD NIH HHS [HD 17013, R01 HD017013] Funding Source: Medline
Ask authors/readers for more resources
According to the concept of immune surveillance, the appearance of a tumor indicates that it has earlier evaded host defenses and subsequently must have escaped immunity to evolve into a full-blown cancer. Tumor escape mechanisms have focused mainly on mutations of immune and apoptotic pathway genes. However, data obtained over the past few years suggest that epigenetic silencing in cancer may be as frequent a cause of gene inactivation as are mutations. Here, we discuss the evidence that tumor immune evasion is mediated by non-mutational epigenetic events involving chromatin and that epigenetics collaborates with mutations in determining tumor progression. Since epigenetic changes are potentially reversible, the relative contribution of mutations and epigenetics, to the gene defects in any given tumor, may be a factor in determining the efficacy of treatments. We review new developments in basic chromatin mechanisms and in this context describe the rationale for the current use of epigenetic agents in cancer therapy and for a novel epigenetically generated tumor vaccine model. We emphasize that epigenetic cancer treatments are currently a 'blunt-sword' and suggest future directions for designing chromatin-based programs of potential value in the diagnosis and treatment of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available